Press release

Alloga UK retain Investors In People Gold Status

Alloga UK was recently assessed by Investors in People (IIP) and we are thrilled to announce that we have again achieved the gold accreditation.

IIP measures companies in a number of areas such as leadership, communications and employee support which will ultimately gauge how colleagues feel about working in a business. Achieving any level in this accreditation, let alone Gold, is no small thing and it is a credit to each and every one of our employees that we have been awarded this Gold Status again.

Alloga UK was originally awarded ‘IIP gold’ back in 2017; we have experienced some big changes since that first award associated firstly with our growth and the addition of 2 new sites (AP7 and AP7a), more employees, increased client activity and secondly the impact on our business of Brexit quickly followed by more than a year of COVID-19 restrictions, and despite all of these challenges we have still achieved gold.

Maintaining gold status reflects a lot of hard work and commitment from members of the Alloga UK team to uphold our reputation as a company that values its people and delivers an exceptional level of service to clients. To still be able to deliver this during such challenging times speaks volumes about the Team we have here at Alloga.

Only 17% of organisations achieve gold and we would like to take the opportunity to thank each and every one of our employees who were involved in the IIP assessment – your passion for the business and your positivity has no doubt helped us to maintain this very high standard.

Of course, there is always room for improvement and from the feedback provided, we have recommendations and action plans across the different departments so that we can keep making changes, keep improving and move forward as a business.

Press release

IntrinsiQ Specialty Solutions Expands Data Capabilities, Empowering Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes

October 16, 2025

Media statement

Cencora to Support Commercial Launch of Precigen’s Novel Immunotherapy in the United States

September 24, 2025

Media mention

ThoughtSpot 2025 Highlights Cencora’s Commitment to Advancing the Future of Pharmacy and Ensuring Medication Access

August 27, 2025

Media contacts

Need help or have questions?  Send us a message and we'll get back to you soon.

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.